Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 3
2002 1
2003 1
2004 1
2005 1
2006 2
2007 2
2010 2
2011 2
2012 3
2013 5
2014 5
2015 5
2016 9
2017 6
2018 3
2019 5
2020 2
2021 6
2023 4
2024 1
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Results by year

Filters applied: . Clear all
Page 1
Cancer cell plasticity defines response to immunotherapy in cutaneous squamous cell carcinoma.
Lorenzo-Sanz L, Lopez-Cerda M, da Silva-Diz V, Artés MH, Llop S, Penin RM, Bermejo JO, Gonzalez-Suarez E, Esteller M, Viñals F, Espinosa E, Oliva M, Piulats JM, Martin-Liberal J, Muñoz P. Lorenzo-Sanz L, et al. Among authors: gonzalez suarez e. Nat Commun. 2024 Jun 24;15(1):5352. doi: 10.1038/s41467-024-49718-8. Nat Commun. 2024. PMID: 38914547 Free PMC article.
Targeting RANKL in metastasis.
Dougall WC, Holen I, González Suárez E. Dougall WC, et al. Among authors: gonzalez suarez e. Bonekey Rep. 2014 Apr 9;3:519. doi: 10.1038/bonekey.2014.14. eCollection 2014. Bonekey Rep. 2014. PMID: 24795813 Free PMC article. Review.
RANK as a therapeutic target in cancer.
González-Suárez E, Sanz-Moreno A. González-Suárez E, et al. FEBS J. 2016 Jun;283(11):2018-33. doi: 10.1111/febs.13645. Epub 2016 Jan 28. FEBS J. 2016. PMID: 26749530 Free article. Review.
Interrogating open issues in cancer precision medicine with patient-derived xenografts.
Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L. Byrne AT, et al. Among authors: gonzalez suarez e. Nat Rev Cancer. 2017 Apr;17(4):254-268. doi: 10.1038/nrc.2016.140. Epub 2017 Jan 20. Nat Rev Cancer. 2017. PMID: 28104906 Free article. Review.
RANK pathway inhibition sensitizes triple-negative breast cancer to CDK4/6 inhibitors and enhances immune response.
Gomes I, Martelo M, Vilela RD, Jimenez M, Trinidad EM, Gómez-Miragaya J, González-Suárez E, Martins É, Torres SS, Corredeira P, Miranda JL, Mansinho A, Torres S, Abreu C, Sousa R, Casimiro S, Costa L. Gomes I, et al. Among authors: gonzalez suarez e. Mol Cancer Ther. 2025 May 30. doi: 10.1158/1535-7163.MCT-24-1158. Online ahead of print. Mol Cancer Ther. 2025. PMID: 40444791
RANK/RANKL Signaling Pathway in Breast Development and Cancer.
Pérez-Chacón G, Santamaría PG, Redondo-Pedraza J, González-Suárez E. Pérez-Chacón G, et al. Among authors: gonzalez suarez e. Adv Exp Med Biol. 2025;1464:309-345. doi: 10.1007/978-3-031-70875-6_16. Adv Exp Med Biol. 2025. PMID: 39821032 Review.
RANKL/RANK control Brca1 mutation-.
Sigl V, Owusu-Boaitey K, Joshi PA, Kavirayani A, Wirnsberger G, Novatchkova M, Kozieradzki I, Schramek D, Edokobi N, Hersl J, Sampson A, Odai-Afotey A, Lazaro C, Gonzalez-Suarez E, Pujana MA, Cimba F, Heyn H, Vidal E, Cruickshank J, Berman H, Sarao R, Ticevic M, Uribesalgo I, Tortola L, Rao S, Tan Y, Pfeiler G, Lee EY, Bago-Horvath Z, Kenner L, Popper H, Singer C, Khokha R, Jones LP, Penninger JM. Sigl V, et al. Among authors: gonzalez suarez e. Cell Res. 2016 Jul;26(7):761-74. doi: 10.1038/cr.2016.69. Epub 2016 May 31. Cell Res. 2016. PMID: 27241552 Free PMC article.
Denosumab as an immune modulator in HER2-negative early breast cancer: results of the window-of-opportunity D-BIOMARK clinical trial.
Vethencourt A, Trinidad EM, Dorca E, Petit A, Soler-Monsó MT, Ciscar M, Barranco A, Pérez-Chacón G, Jimenez M, Rodríguez M, Gomez-Aleza C, Purqueras E, Hernández-Jiménez E, Urruticoechea A, Morilla I, Subirana I, García-Tejedor A, Gil-Gil M, Pernas S, Falo C, Gonzalez-Suarez E. Vethencourt A, et al. Among authors: gonzalez suarez e. Breast Cancer Res. 2025 May 12;27(1):68. doi: 10.1186/s13058-025-01996-w. Breast Cancer Res. 2025. PMID: 40350430 Free PMC article. Clinical Trial.
68 results